Filtered By:
Condition: Hypertension
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 319 results found since Jan 2013.
Characteristics of Ischemic Versus Hemorrhagic Stroke in Patients Receiving Oral Anticoagulants: Results of the PASTA Study
Conclusion The presence of CMBs, a history of stroke, natriuretic peptide and D-dimer levels, and PT-INR may be useful for risk stratification of either IS/TIA or ICH development in patients with AF receiving OACs.PMID:34483213 | DOI:10.2169/internalmedicine.8113-21
Source: Internal Medicine - September 6, 2021 Category: Internal Medicine Authors: Satoshi Suda Arata Abe Yasuyuki Iguchi Yoshiki Yagita Takao Kanzawa Seiji Okubo Nobuyuki Ohara Takayuki Mizunari Mineo Yamazaki Nobuhito Nakajima Kimito Kondo Shigeru Fujimoto Takeshi Inoue Takeshi Iwanaga Yuka Terasawa Kensaku Shibazaki Yu Kono Makoto Na Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
No effect of calcium and vitamin D intake on maternal blood pressure in a healthy pregnant population
Pregnancy causes physiological changes in blood pressure (BP). In patients without pre-existing hypertension, BP falls during the first half of pregnancy and rises from 34 weeks onwards [1]. Hypertensive disorders in pregnancy (HDP) complicate approximately 10% of pregnancies and are associated with adverse outcomes for both mother and foetus [2]. Women with a history of HDP are also at increased risk of developing hypertension in later life as well as ischaemic heart disease, stroke and renal disease [3].
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - July 6, 2021 Category: OBGYN Authors: Hannah Forde, Rachel K. Crowley, Malachi J. McKenna, Mark T. Kilbane, Marie Conway, Ciara M. McDonnell, Patrick J. Twomey, Fionnuala M. McAuliffe Tags: Full length article Source Type: research
Association between serum Vitamin E concentrations and the presence of Metabolic Syndrome: A population-based cohort study
Conclusions. There is a significant inverse association between indices of Vit E status and the presence of MetS. Moreover, a significantly lower Vit E/ (TC+TG) was observed along with individuals with increasing numbers of components of the MetS.PMID:34212939 | DOI:10.23750/abm.v92i3.9173
Source: Acta Bio-Medica : Atenei Parmensis - July 2, 2021 Category: General Medicine Authors: Maral Barzegar-Amini Fateme Khorramruz Hamideh Ghazizadeh Reza Sahebi Maryam Mohammadi-Bajgyran Hossein Mohaddes Ardabili Maryam Tayefi Susan Darroudi Mohsen Moohebati Alireza Heidari-Bakavoli Akram Mohammadi Hamid Reza Sadeghnia Gordon A Ferns Seyed Java Source Type: research
